Opko Health Inc.

OPK Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
OPK Income Statement
OPK Balance Sheet
OPK Cash Flow
Congress Trading

Recent trades of OPK by members of U.S. Congress

Politician Type Traded
Carlos Curbelo House / R Purchase $1,001 - $15,000 Sep. 26, 2017
Carlos Curbelo House / R Purchase $1,001 - $15,000 Mar. 02, 2017
Carlos Curbelo House / R Purchase $1,001 - $15,000 Feb. 07, 2017
OPK Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
OPK Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
OPK Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by OPK's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $25,000 Oct 31, 2024 Issue: Health Issues
  • $25,000 Jul 30, 2024 Issue: Health Issues
  • $25,000 Apr 04, 2024 Issue: None
  • $25,000 Feb 05, 2024 Issue: Health Issues
  • $25,000 Oct 02, 2023 Issue: Health Issues
  • $25,000 Aug 04, 2023 Issue: Health Issues
  • $50,000 Jan 08, 2023 Issue: Health Issues
  • $50,000 Nov 02, 2022 Issue: Health Issues
  • $50,000 Jul 07, 2022 Issue: Health Issues
  • $50,000 May 05, 2022 Issue: Health Issues
  • $50,000 Feb 09, 2022 Issue: Health Issues
  • $50,000 Nov 03, 2021 Issue: Health Issues
  • $50,000 Aug 05, 2021 Issue: Health Issues
  • $50,000 May 03, 2021 Issue: Health Issues
  • $50,000 Feb 03, 2021 Issue: Health Issues
  • $60,000 Nov 04, 2020 Issue: Health Issues
  • $50,000 Aug 05, 2020 Issue: Health Issues
  • $50,000 Apr 26, 2020 Issue: Health Issues
  • $50,000 Jan 23, 2020 Issue: Health Issues
  • $51,000 Nov 18, 2019 Issue: Health Issues
  • $37,000 Jul 30, 2019 Issue: Health Issues
  • $37,000 Jul 30, 2019 Issue: Health Issues
  • $25,000 Aug 17, 2016 Issue: Health Issues
  • $25,000 Jul 06, 2016 Issue: None
  • $36,000 Mar 31, 2015 Issue: Health Issues
  • $40,000 Jan 20, 2015 Issue: Health Issues Veterans Medicare/Medicaid
  • $45,000 Nov 16, 2014 Issue: Health Issues Veterans Government Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Hydrochloride salts of 8-[1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one and preparation process therefor Feb. 05, 2019
  • Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Jun. 19, 2018
  • Patent Title: Nk May. 15, 2018
  • Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Nov. 21, 2017
  • Patent Title: Nk Jun. 27, 2017
  • Patent Title: Nk Oct. 18, 2016
  • Patent Title: Pharmaceutical formulations: salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxy-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same May. 24, 2016
  • Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Feb. 16, 2016
  • Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Feb. 02, 2016
  • Patent Title: Intravenous formulations of neurokinin-1 antagonists Aug. 11, 2015
  • Patent Title: Hypersulfated disaccharide formulations Apr. 14, 2015
  • Patent Title: Nk1 antagonists Aug. 05, 2014
  • Patent Title: Nk1 antagonists Jun. 17, 2014
  • Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Oct. 08, 2013
  • Patent Title: Hypersulfated disaccharide formulations Oct. 01, 2013
  • Patent Title: Hydrochloride salts of 8-[{1-(3,5-bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor Jun. 25, 2013
  • Patent Title: Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Mar. 26, 2013
  • Patent Title: Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom Jan. 29, 2013
  • Patent Title: Nk Sep. 25, 2012
  • Patent Title: Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor May. 15, 2012
  • Patent Title: Nk Sep. 27, 2011
  • Patent Title: Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Jul. 19, 2011
  • Patent Title: Nk Mar. 08, 2011
  • Patent Title: Nk1 antagonists May. 04, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of OPK in WallStreetBets Daily Discussion

OPK News

Recent insights relating to OPK

CNBC Recommendations

Recent picks made for OPK stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in OPK

OPK Top Shareholders
Shareholder
Shares Held
OPK Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

OPK Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view OPK Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top